| Literature DB >> 27919257 |
Jo-Ann Mulligan1,2, Lesong Conteh3.
Abstract
BACKGROUND: As global research investment increases, attention inevitably turns to assessing and measuring the outcomes and impact from research programmes. Research can have many different outcomes such as producing advances in scientific knowledge, building research capacity and, ultimately, health and broader societal benefits. The aim of this study was to test the use of a Delphi methodology as a way of gathering views from malaria research experts on research priorities and eliciting relative valuations of the different types of health research impact.Entities:
Keywords: Delphi; Global health; Malaria; Payback; Research assessment; Research priorities
Mesh:
Year: 2016 PMID: 27919257 PMCID: PMC5139033 DOI: 10.1186/s12936-016-1628-4
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
The payback approach to classifying the different outcomes from research
| Category descriptions |
|---|
|
|
|
|
|
|
|
|
|
|
Fig. 1Respondents/non-respondents at each stage of the process
Fig. 2Professional affiliation of participants
Fig. 3Place of residence of participants
Fig. 4Years of relevant work experience of participants
Fig. 5Ranked most important past developments in malaria research
A selection of free text responses to the question: “What has surprised you most about developments in malaria research in the last 20 years?”
| “The limited progress made in developing a truly effective malaria vaccine”. (other professional affiliation, high-income country) |
| “The continued investments in vaccines and genomic solutions at the expenses of investments in vector control which have saved more children (than) any other intervention in the present and the previous malaria elimination campaigns” (Academia, high-income country) |
| “That operational research is not more important” (Academia, high-income country) |
| “Low interest and lack of funding in malaria compared to new diseases such as HIV, few innovations in new effective malaria control tools” (National government, low-income country) |
| “The unprecedented rise in the investment in malaria research in malaria endemic countries largely due to support from external funders. Despite this global effort how relatively little domestic funding government in malaria endemic countries continue to invest in malaria research” (Academia, low-income country) |
| “After working for 30 years on malaria control in Africa I was amazed when malaria started to decline in many African countries” (Academia, high-income country) |
| “Most surprising has been that lack of “true innovation” in malaria community. Our current best tools are still also our oldest” (Non-government organization, low-income country) |
| “The enormous disparity between research and policy, and the parallel universes of the research and international health/donor communities” (Academia, low-income country) |
| “The little investments in health systems research—understanding how health systems could improve effective coverage of malaria interventions” (Academia, high-income country) |
| “The slow progress from research into policy following the discovery of ACT while there was evidence that chloroquine resistance was associated with increased mortality” (Academia, middle-income country) |
Fig. 6Ranked priority areas for malaria research investment in the next 20 years
Fig. 7Ranked most important global health issues in the next 20–50 years
In your opinion, what issues of global health importance today will be less important in the future?
| Description | No. of mentions (n = 44) | % |
|---|---|---|
| Communicable diseases and the ‘classical infections’ | 16 | 36 |
| Neglected tropical diseases | 5 | 11 |
| HIV management | 4 | 9 |
| Diseases related to hygiene and sanitation, such as cholera | 2 | 5 |
| New emerging diseases | 2 | 5 |
| Inequities | 1 | 2 |
| Vaccines aimed at reducing mortality rather than interrupting or eliminating transmission | 1 | 2 |
| Car accidents | 1 | 2 |
| Famines | 1 | 2 |
| Fundamental studies of immunology, vaccinology and transgenics | 1 | 2 |
| Cancer and obesity | 1 | 2 |
| Commodity procurement | 1 | 2 |
| Don’t know | 8 | 18 |
Question asked in round 1 only
What percentage weight would you give to each of the following outcome categories, in terms of their importance to overall research impact?
| Research outcome category | Round 1 (n = 54) | Round 2 (n = 49) | ||
|---|---|---|---|---|
| Mean value | Std. err. | Mean value | Std. err. | |
| Contribution to knowledge | 19.6 | 2.47 | 18.9 | 0.53 |
| Benefits to future research and research use | 17.3 | 1.06 | 16.6 | 0.43 |
| Benefits from informing policy and product development | 25.4 | 1.56 | 25.4 | 0.26 |
| Health and health sector benefits | 25.6 | 1.45 | 26.3 | 0.40 |
| Broader economic benefits | 12.0 | 1.04 | 12.9 | 0.42 |